Material from theraputic vaccines - too technical 

The following was added to the therapeutic vaccines section recently.  I am not sure whether it should just be removed, or if there is material here that once simplified might be useful to include.

HPV-associated neoplasia are being used to test antigen specific immunotherapies. Therapies have focused on HPV's susceptibility to immune manipulation. Imiquimod, a toll-like receptor (TLR) 7 agonist, works as an inducer of natural immune responses and has been approved by the FDA as first-line therapy for external genital warts.  

  Focus has been put on testing T-cell responses to HPV E6 or E7 in intraepithelial lesions. Therapeutic HPV vaccines work to induce increased T-cell responses in humans. In clinical trials, these therapies were administered through different delivery systems such as fusion proteins used alone and with adjuvant, encapsulated polynucleotides, protein with adjuvant, recombinant viruses, DNA constructs, dendritic cells, and chimeric VLP constructs. While patients part of this clinical testing showed limited benefit from therapeutic induced T-cells responses, they were poor targets for antigen-specific therapies. The patients had late-stage disease, giving the tumors more time to develop mutations as well as deletions of genes involved in antigen processing and presentation.

The first paragraph has no obvious relation to vaccines, since it appears to be talking about other types of therapies.  If it relates to vaccines somehow, that needs to be clarified.  The other paragraph is too technical without enough explanation to make it comprehensible.  

Please see WP:MEDMOS, both for language/audience, and a little bit on what should be in a research section.  Research sections are not for detailed explanations of the research, but to indicate major directions and progress, if there is coverage in significant sources.  (e.g. a review of research in an area might be a decent source, individual research papers - much more problematic).